Company: RNGE
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023395
Chunk: 111

Company: RANGE IMPACT, INC.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 8
Chunk 111
---
 of $3,043,799 on the sale of the Collins Building assets.
This sale does not constitute a discontinued operation as the Company has ongoing activities related to its acquisition of Collins
Building, and only certain assets were sold and debts forgiven. As of March 31, 2025, any remaining active projects related to
Collins Building will be completed by the previous owner or his subcontractors at the previous owner’s expense.

On
September 30, 2024, the Company sold all of the common stock of Graphium Biosciences, Inc., its wholly-owned subsidiary, to a newly-formed entity, Placer Biosciences, Inc.
(“Placer”), owned by two former officers of the Company, in exchange for a warrant to purchase 1,000 shares of Placer’s
common stock (then representing 25% of the outstanding shares of Placer) at $0.01 per share and cash proceeds of $100. The warrant to
purchase shares of Placer’s common stock expires on September 30, 2034.

Loss
from Discontinued Operations

Discontinued
operations for the three and nine months ended September 30, 2024 consists of results from Graphium Biosciences operations. The
Company had no discontinued operations for either the three or nine months ended September 30, 2025. The following table provides
details about the major classes of line items constituting “Loss from discontinued operations” presented on the
Company’s Consolidated Statements of Operations:

SCHEDULE
OF DISCONTINUING OPERATIONS INCOME STATEMENT 

    Three Months Ended September 30,
                                                                                                                                                                                                                                                                               2024  
    Nine Months Ended September 30,
                                                                                                                                                                                                                                                                               2024  

    Operating expenses: 

    Research and development 
    $177,015  
    $465,933 
  
    Total operating expenses 
     177,015  
     465,933 

    Loss from discontinued operations 
    $(177,015) 
    $(465,933)

5.
EQUITY

Issuance
of Common Stock

On
January 21, 2025, the Company entered into a securities purchase agreement for the issuance and sale of 3,333,333 shares of the Company’s
common stock at a price of $0.15 per share. The aggregate proceeds to the Company were approximately $500,000.

On
February 6, 2025, the Company entered into a securities purchase